The Society for Immunotherapy of Cancer (SITC) is currently recruiting practices for clinician-level testing of the draft quality measure: Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint Inhibitor Therapy.
If interested, please take the time to fill out this short interest form by 01/05/2023.
Participating practices will answer approximately 30 questions via Survey Monkey on a random sample of at least 25 patients with metastatic non-small cell lung cancer and/or squamous cell carcinoma of the head and neck who received first-line immune checkpoint inhibitors without chemotherapy. No Protected Health Information (PHI) will be collected. The estimated time commitment to enter data is 5 to 6 hours, and SITC will provide detailed instructions before we ask you to start. Participating practices will receive financial support for these efforts.
SITC is committed to advancing IO patient care through quality improvement. If you have any questions or would like additional information, please contact email@example.com. SITC is happy to take referrals of practices or individuals interested in participating as well. Please forward all referrals to firstname.lastname@example.org.